GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease
| Status: | Completed |
|---|---|
| Conditions: | Alzheimer Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 50 - 80 |
| Updated: | 10/14/2017 |
| Start Date: | November 2006 |
| End Date: | April 2007 |
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of
GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days
to Participants With Probable Alzheimer’s Disease
GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days
to Participants With Probable Alzheimer’s Disease
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of
GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days
to Participants With Probable Alzheimer’s Disease
GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days
to Participants With Probable Alzheimer’s Disease
Inclusion Criteria:
- probable Alzheimer
Exclusion Criteria:
- others
We found this trial at
1
site
Click here to add this to my saved trials
